Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk Halts Ozempic Study
10:37am, Wednesday, 11'th Oct 2023
Novo Nordisk is halting a study which looked at the impact of its blockbuster Ozempic drug on kidney failure after it showed effectiveness surprisingly early. Ed Ludlow reports.
Novo Nordisk (NVO) Up on Positive Kidney Outcomes Study Update
10:32am, Wednesday, 11'th Oct 2023
Novo Nordisk (NVO) is set to stop its kidney outcomes study on Ozempic based on interim analysis results that met certain pre-specified efficacy criteria for early closure. The stock rises 5.2%.
Novo Nordisk data knocks $5bn from the value of three leading dialysis companies
09:44am, Wednesday, 11'th Oct 2023
Over $5bn in value was wiped from the three main operators in the dialysis market after a clinical trial update that offers hope for thousands of diabetes sufferers with kidney disease. Earlier, Novo
Ozempic Is Moving a Bunch of Stocks Wednesday Morning
09:37am, Wednesday, 11'th Oct 2023
Markets were poised to move higher again on Wednesday morning. Shares of Novo Nordisk climbed on good news from a study of its drug Ozempic on kidney patients.
New Strong Sell Stocks for October 11th
08:17am, Wednesday, 11'th Oct 2023
NVO, MT and PRPL have been added to the Zacks Rank #5 (Strong Sell) List on October 11, 2023.
Is Novo Nordisk Stock a Buy Now?
07:37am, Wednesday, 11'th Oct 2023
GLP-1 drugs are combating the addictive properties of sugars and junk foods. Novo Nordisk has tens of millions of potential patients it can treat.
Novo Nordisk Halts Ozempic Kidney Trial. Why It's Bad for DaVita.
07:24am, Wednesday, 11'th Oct 2023
Novo Nordisk's Ozempic already is poised to disrupt a range of industries via its weight-loss benefits. Now it threatens companies which treat kidney failure.
Novo Nordisk shares rise, Silk Road Medical stock slumps and other movers
05:50am, Wednesday, 11'th Oct 2023
Shares of Thor Industries Inc. THO rose 2% after the RV maker said its board authorized a 7% dividend increase to 48 cents a share.
Novo Nordisk to stop Ozempic trial to treat renal impairment early
05:30pm, Tuesday, 10'th Oct 2023
Denmark-based drugmaker Novo Nordisk said on Tuesday it will stop a trial studying Ozempic, its popular diabetes and weight-loss drug, to treat renal impairment in diabetes patients, as its independen
How Ozempic and Wegovy turned Novo Nordisk into a $400 billion company
11:00am, Tuesday, 10'th Oct 2023
How Ozempic and Wegovy turned Novo Nordisk into a $400 billion company
Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note
07:32pm, Monday, 09'th Oct 2023
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $92.06, denoting a -0.07% change from the preceding trading day.
How Ozempic Accidentally Made Novo Nordisk A $400B Company
12:30pm, Monday, 09'th Oct 2023
Pharmaceutical giant, Novo Nordisk, is now Europe's most valuable company, worth more than its home country, Denmark's total economy. That wasn't always the case, and only recently, through its popula
3 No-Brainer Growth Stocks to Buy in October
06:53am, Saturday, 07'th Oct 2023
Eli Lilly is crushing the market because of its impressive product lineup and strong prospects. Novo Nordisk is just getting warmed up with a massive opportunity for Ozempic and Wegovy.
Better Growth Stock: Novo Nordisk vs. Pfizer
09:45am, Friday, 06'th Oct 2023
Pfizer has been actively acquiring companies as it looks to bolster its future growth prospects. Novo Nordisk's top weight-loss drug has more than quadrupled sales and there's more growth ahead.
2 Reasons Why Eli Lilly's Mounjaro Might Beat Novo Nordisk's Ozempic, and 2 Reasons Why It Might Not
08:15am, Friday, 06'th Oct 2023
Ozempic and Mounjaro are key drugs for Novo Nordisk and Eli Lilly, respectively. Both treat most of the same conditions, and both are major drivers of earnings.
